Sol-Gel to acquire rare disorder drug patidegib for $4.7M upfront; plans $22.8M offerings

Shot of a businessman and businesswoman shaking hands in a modern office

Delmaine Donson

Sol-Gel Technologies (NASDAQ:SLGL) said it is acquiring topically-applied drug patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings.

Sol-Gel will pay PellePharm $4.7M upfront and total development and NDA acceptance milestones of up to $6M, and up

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!